Lixte Biotechnology (LIXT) CEO cancels 350K options for shares

Rhea-AI Filing Summary

Lixte Biotechnology CEO Geordan Garrett Pursglove restructured his equity compensation on April 15, 2026. He agreed to cancel 350,000 options to purchase common stock with a $2.83 exercise price that were scheduled to expire on July 3, 2030, returning them to the company.

In exchange, he received 350,000 shares of common stock as a grant or award tied to 350,000 restricted share units under the 2020 Stock Incentive Plan. These RSUs vest immediately upon grant, so he now directly holds 350,000 common shares after the transaction. The filing shows no open‑market buying or selling; it is an issuer disposition of options paired with a compensatory stock award.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Pursglove Geordan Garrett

Role CEO and Chairman of the Board

Type	Security	Shares	Price	Value
Disposition	Options to Purchase Common Stock	350,000	$0.00	--
Grant/Award	Common Stock	350,000	$0.00	--

Holdings After Transaction: Options to Purchase Common Stock — 0 shares (Direct); Common Stock — 350,000 shares (Direct)

Footnotes (1)

1. On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 350,000 options (the "Options") granted to the Reporting Person on July 3, 2025. In exchange for the Options, the Reporting Person received 350,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 350,000 RSUs vest immediately upon grant. The canceled Options provided for vesting 50% on the effective date, 25% on September 30,2025 and 25% on December 31,2025.

Key Figures

Options canceled: 350,000 options Exercise price: $2.83 per share Options expiration: July 3, 2030 +3 more

6 metrics

Options canceled 350,000 options Options to purchase common stock disposed to issuer on April 15, 2026

Exercise price $2.83 per share Exercise price of canceled options

Options expiration July 3, 2030 Original expiration date of canceled options

Shares granted 350,000 shares Common stock granted via award on April 15, 2026

Shares held after 350,000 shares Direct common stock ownership following the transactions

RSUs granted 350,000 RSUs Restricted share units granted under 2020 Stock Incentive Plan, vest immediately

Key Terms

Stock Option Cancellation Agreement, restricted share units, 2020 Stock Incentive Plan, Disposition to issuer, +1 more

5 terms

Stock Option Cancellation Agreement financial

"the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026"

restricted share units financial

"In exchange for the Options, the Reporting Person received 350,000 restricted share units ("RSUs")"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2020 Stock Incentive Plan financial

"The RSUs were granted pursuant to the applicable award agreement ... and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan"

Disposition to issuer financial

"transaction_code_description: "Disposition to issuer" for the options transaction"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition" for the common stock"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pursglove Geordan Garrett

(Last) (First) (Middle)

433 PLAZA REAL, SUITE 275

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman of the Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		A		350,000	A	(1)	350,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock	$2.83	04/15/2026		D			350,000	(2)	07/03/2030	Common	350,000	(1)	0	D

Explanation of Responses:

1. On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 350,000 options (the "Options") granted to the Reporting Person on July 3, 2025. In exchange for the Options, the Reporting Person received 350,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 350,000 RSUs vest immediately upon grant.

2. The canceled Options provided for vesting 50% on the effective date, 25% on September 30,2025 and 25% on December 31,2025.

	/s/ Geordan Pursglove	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LIXT report for CEO Geordan Pursglove?

Lixte Biotechnology reported that CEO Geordan Garrett Pursglove canceled 350,000 stock options and, in exchange, received 350,000 common shares via a compensatory grant on April 15, 2026. This is a restructuring of his equity package, not an open‑market trade.

How many LIXT stock options were canceled in the latest Form 4?

The Form 4 shows 350,000 options to purchase Lixte common stock were canceled and returned to the issuer. These options carried a $2.83 exercise price and a July 3, 2030 expiration, and were replaced with an equivalent number of shares through a stock award.

What did the LIXT CEO receive for canceling 350,000 options?

For canceling 350,000 options, the Lixte CEO received 350,000 shares of common stock via a grant linked to restricted share units. The RSUs were granted under the 2020 Stock Incentive Plan and vest immediately, resulting in 350,000 common shares held directly after the transaction.

Did the LIXT CEO buy or sell shares on the open market?

The filing does not show any open‑market purchases or sales. Instead, it reports an issuer disposition of 350,000 options and a compensatory grant of 350,000 common shares, restructuring the CEO’s equity holdings without a market trade at a stated share price.

How many LIXT shares does the CEO hold after this Form 4 transaction?

After the reported transactions, the Form 4 lists 350,000 shares of Lixte common stock directly owned by the CEO. These shares stem from the grant replacing his canceled options and reflect his post‑transaction direct equity position disclosed in the filing.